IMVT — Immunovant, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1764013 ·
Last close
$43.32
Market Cap
$8.95B
52W High
$45.42
52W Low
$30.24
ADV30
1,029,865
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -160,323,000 | -153,224,000 | 852,490,000 | 797,798,000 | 117,102,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -114,362,000 | -110,635,000 | 1,052,392,000 | 994,525,000 | 66,257,000 |
| Sep 2025 | 0 | — | -131,762,000 | -126,502,000 | 582,959,000 | 521,870,000 | 63,254,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-414,304,000
Investing CF
$-8,000
Financing CF
$612,935,000
CapEx
$-381,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.82
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,898,353,000
Inventory
—
Receivables
$697,000
ST Investments
—
EBIT TTM
$-566,001,000
Pretax Income TTM
$-538,915,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -532,902,000 | -505,606,000 | 957,014,000 | 104,422,000 | — | -407,310,000 |
| Mar 2025 | 0 | -438,152,000 | -413,840,000 | 776,222,000 | 68,775,000 | — | -375,874,000 |
| Mar 2024 | 0 | -270,209,000 | -259,336,000 | 666,365,000 | 48,608,000 | — | -214,227,000 |
| Mar 2023 | 0 | -208,276,000 | -210,960,000 | 405,838,000 | 43,344,000 | — | -188,193,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-267,152,000
OpCashFlow TTM
$0
Assets (Latest)
$776,222,000
Forward EPS
$-2.75
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $39.00 · spot: $43.32 · call volume: 79 · put volume: 1,570
Expected Move to 2026-09-18:
±$6.01
(13.87%) —
implied range
$37.31 –
$49.33
· ATM straddle on $43.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TWST | Twist Bioscience Corp | $8.83B | $140.80 | — |
| PCVX | Vaxcyte, Inc. | $9.21B | $61.87 | — |
| QGEN | QIAGEN N.V. | $8.63B | $41.78 | — |
| APGE | Apogee Therapeutics, Inc. | $8.38B | $134.79 | — |
| IBRX | ImmunityBio, Inc. | $8.03B | $7.58 | — |
News headlines (Yahoo Finance, 1h cache)
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says
2026-08-24 17:16 · Yahoo
Immunovant (IMVT) Q1 2027 Earnings Call Transcript
2026-08-13 12:01 · Yahoo
Immunovant Q1 Earnings Call Highlights
2026-08-06 19:04 · Yahoo
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
2026-08-06 11:00 · Yahoo
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
2026-07-23 20:05 · Yahoo
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
2026-06-05 08:12 · Yahoo
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
2026-05-28 11:01 · Yahoo
Immunovant, Inc. Q1 2027 Earnings Call Summary
2026-08-06 21:51 · Yahoo
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
2026-08-06 15:22 · Yahoo
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
2026-06-19 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.